{"id":968317,"date":"2026-05-28T16:24:16","date_gmt":"2026-05-28T20:24:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/"},"modified":"2026-05-28T16:24:16","modified_gmt":"2026-05-28T20:24:16","slug":"emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/","title":{"rendered":"Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy"},"content":{"rendered":"
\n

GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT\u00ae<\/sup>\u00a0[Botulism Antitoxin Heptavalent (A, B,\u00a0C, D, E,\u00a0F, G) \u2013 (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT\u00ae<\/sup>, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B,\u00a0C, D, E, F, or G in both adults and pediatric patients.<\/p>\n

\u201cSecuring this contract modification demonstrates Emergent\u2019s ongoing support of U.S. biodefense and preparedness priorities,\u201d said Paul Williams, head of products business, global government & public affairs at Emergent. \u201cWe are proud to leverage our North American supply chain and specialized capabilities to deliver critical medical countermeasures to help protect military and civilian populations.\u201d<\/p>\n

Emergent specializes in developing,\u202fmanufacturing\u202fand supplying medical countermeasures for national security and health preparedness through its network of USMCA-compliant facilities. These products support how the U.S. and allied governments respond to emergencies and help protect the public from potential threats.<\/p>\n

\n Indication and Important Safety Information for BAT<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n \u00a0<\/strong>\n <\/p>\n

BAT\u00ae<\/sup>\u00a0is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B,\u00a0C, D, E, F, or G in adults and pediatric patients. The effectiveness of BAT\u00ae<\/sup> is based solely on efficacy studies conducted in animal models of botulism.<\/p>\n

\n Warnings and Precautions: <\/strong>
\n
\n Hypersensitivity reactions including anaphylaxis<\/u>
\n <\/em>. Prepare for monitoring and management of allergic reactions during and after BAT\u00ae<\/sup> infusion. Delayed allergic reactions (serum sickness)<\/u><\/em>. Patient monitoring is recommended. Infusion reactions<\/u><\/em>. Monitor and slow or interrupt infusion and administer treatment based on the severity of the reaction. Interference with non-glucose specific blood sugar testing systems<\/u><\/em>. Use glucose-specific testing systems. Transmissible Infectious Agents<\/u><\/em>. BAT\u00ae<\/sup> is made from equine plasma and may contain infectious agents (e.g., viruses).<\/p>\n

\n Adverse Reactions: <\/strong>The most common adverse reactions observed in \u22655% of healthy volunteers in clinical trials were headache, nausea, pruritus, and urticaria. The most common adverse reactions reported in \u22651% of patients in a clinical study were pyrexia, rash, chills, nausea, and edema. One serious adverse reaction of hemodynamic instability was observed in one patient in the clinical study.<\/p>\n

Please see full\u00a0Prescribing Information<\/a>\u00a0for BAT\u00ae<\/sup> for additional safety information.<\/p>\n

\n About\u00a0Emergent BioSolutions\u00a0<\/strong>
\n
At Emergent, our mission is to protect and save lives. For over 25 years, we\u2019ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today\u2019s health challenges and tomorrow\u2019s threats, visit our\u00a0website<\/a>\u00a0and follow us on\u00a0LinkedIn<\/a>,\u00a0X<\/a>,\u00a0Instagram<\/a>,\u00a0Apple Podcasts<\/a>\u00a0and\u00a0Spotify<\/a>.\u00a0<\/p>\n

\n Safe Harbor Statement<\/strong>
\n
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the development, availability, and government procurement of BAT\u00ae<\/sup>\u00a0are forward-looking statements. We generally identify forward-looking statements by using words like \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cforecast,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the\u00a0U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.<\/p>\n

\n Investor Contact:<\/strong>
\n
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT\u00ae\u00a0[Botulism Antitoxin Heptavalent (A, B,\u00a0C, D, E,\u00a0F, G) \u2013 (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT\u00ae, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B,\u00a0C, D, E, F, or G in both adults and pediatric patients. \u201cSecuring this contract modification demonstrates Emergent\u2019s ongoing support of U.S. biodefense … <\/p>\n

Continue reading “Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-968317","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEmergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT\u00ae\u00a0[Botulism Antitoxin Heptavalent (A, B,\u00a0C, D, E,\u00a0F, G) \u2013 (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT\u00ae, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B,\u00a0C, D, E, F, or G in both adults and pediatric patients. \u201cSecuring this contract modification demonstrates Emergent\u2019s ongoing support of U.S. biodefense … Continue reading "Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T20:24:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODQ5NSM3NjI2MzI0IzIwMTA4NjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy\",\"datePublished\":\"2026-05-28T20:24:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/\"},\"wordCount\":761,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODQ5NSM3NjI2MzI0IzIwMTA4NjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/\",\"name\":\"Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODQ5NSM3NjI2MzI0IzIwMTA4NjY=\",\"datePublished\":\"2026-05-28T20:24:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODQ5NSM3NjI2MzI0IzIwMTA4NjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODQ5NSM3NjI2MzI0IzIwMTA4NjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/","og_locale":"en_US","og_type":"article","og_title":"Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy - Market Newsdesk","og_description":"GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT\u00ae\u00a0[Botulism Antitoxin Heptavalent (A, B,\u00a0C, D, E,\u00a0F, G) \u2013 (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT\u00ae, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B,\u00a0C, D, E, F, or G in both adults and pediatric patients. \u201cSecuring this contract modification demonstrates Emergent\u2019s ongoing support of U.S. biodefense … Continue reading \"Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-28T20:24:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODQ5NSM3NjI2MzI0IzIwMTA4NjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy","datePublished":"2026-05-28T20:24:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/"},"wordCount":761,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODQ5NSM3NjI2MzI0IzIwMTA4NjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/","name":"Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODQ5NSM3NjI2MzI0IzIwMTA4NjY=","datePublished":"2026-05-28T20:24:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODQ5NSM3NjI2MzI0IzIwMTA4NjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODQ5NSM3NjI2MzI0IzIwMTA4NjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/emergent-biosolutions-receives-64-5-million-contract-modification-for-bat-botulism-antitoxin-heptavalent-a-b-c-d-e-f-g-equine-to-support-u-s-biodefense-strategy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT\u00ae [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) \u2013 (Equine)] to Support U.S. Biodefense Strategy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=968317"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968317\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=968317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=968317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=968317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}